APTITUDE MEDICAL SYSTEMS INC
Aptamer-based combination therapeutics targeting multiple biomarkers for diabetic macular edema treatment
- Sector
- Biotech
- Headquarters
- Santa Barbara, CA
- Total capital
- $56.2M
- Federal grants
- $19.7M
- 39 awards · 2014–2023
- Rank in peer group#71 of 514
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- $36.5M
- 5 awards · Defense, Health and Human S
- Rank in Biotech#25 of 4373
- Granted patents
- 4
- 15 pending · first 2021
- Rank in peer group#85 of 514
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Fully modified bispecific aptamer for effective combination therapy of neovascular ocular diseases$756K
- Federal contractHealth and Human S · Ace Rapid Molecular Test System For Point Of Care (poc) And In-home Use With Saliva And Swab Samples For COVID-19 And Beyond$33.8M
- Federal contractDefense · Award Of Aptitude's Dha SBIR Phase III Follow-on Medical R&d Contract For "real- Time Small-volume Blood Sampling And Analysis For Coagulopathy Of Trauma Analytes"$1.0M
- Federal grantHealth and Human S · Phase I · Developing multi-specific aptamers for safe, potent, and long-lasting treatment of geographic atrophy$248K
- Federal grantHealth and Human S · Phase II · Developing multi-specific aptamers for safe, potent, and long-lasting treatment of geographic atrophy$248K
- Federal grantHealth and Human S · Phase II · Fully modified bispecific aptamer for effective combination therapy of neovascular ocular diseases$744K
- Federal grantHealth and Human S · Phase II · Fully modified bispecific aptamer for effective combination therapy of neovascular ocular diseases$1.5M
Show 37 earlier federal awards
- Federal grantHealth and Human S · Phase I · Developing a multivalent agent for long-lasting treatment of diabetic macular edema$225K
- Federal grantHealth and Human S · Phase II · Developing a multivalent agent for long-lasting treatment of diabetic macular edema$225K
- Federal grantHealth and Human S · Phase II · Targeting SDF-1 for effective wet AMD treatment$805K
- Federal grantHealth and Human S · Phase II · Targeting SDF-1 for effective wet AMD treatment$1.7M
- Federal grantHealth and Human S · Phase II · Targeting SDF-1 for effective wet AMD treatment$912K
- Federal contractDefense · Award Of Aptitude's Dha SBIR Phase II Enhancement Medical R&d Contract For "real- Time Small-volume Blood Sampling And Analysis For Coagulopathy Of Trauma Analytes"$550K
- Federal grantHealth and Human S · Phase II · Fully modified bispecific aptamer for effective combination therapy of neovascular ocular diseases$225K
- Federal grantHealth and Human S · Phase I · Targeting PDGFs for Potential Treatment of Proliferative Vitreoretinopathy$225K
- Federal grantHealth and Human S · Phase II · Targeting SDF-1 for effective wet AMD treatment$283K
- Federal grantHealth and Human S · Phase I · Targeting PDGFs for Potential Treatment of Proliferative Vitreoretinopathy$225K
- Federal grantHealth and Human S · Phase II · Scalable High Quality Aptamer Generation via Chemically-Augmented Particle Display$534K
- Federal grantHealth and Human S · Phase I · Aptamer-enabled multiplex electrochemical sensor for robust and efficient assessment of flu vaccine potency$223K
- Federal grantHealth and Human S · Phase I · Aptamer-enabled multiplex electrochemical sensor for robust and efficient assessment of flu vaccine potency$223K
- Federal grantHealth and Human S · Phase I · Topical delivery of therapeutic aptamers$293K
- Federal grantHealth and Human S · Phase I · Sustained release of next-generation aptamers to treat wet AMD$300K
- Federal grantHealth and Human S · Phase II · Scalable High Quality Aptamer Generation via Chemically-Augmented Particle Display$227K
- Federal grantHealth and Human S · Phase I · Point-of-care testing of fibrinogen for early detection and management of trauma coagulopathy$220K
- Federal grantHealth and Human S · Phase I · Point-of-care testing of fibrinogen for early detection and management of trauma coagulopathy$220K
- Federal grantHealth and Human S · Phase II · Scalable High Quality Aptamer Generation via Chemically-Augmented Particle Display$919K
- Federal grantHealth and Human S · Phase II · Scalable High Quality Aptamer Generation via Chemically-Augmented Particle Display$1.7M
- Federal grantHealth and Human S · Phase II · Real-time Point of Care Insulin Monitoring Device for Improved Diabetes Management$640K
- Federal grantHealth and Human S · Phase I · Targeting SDF for effective wet AMD treatment$250K
- Federal grantHealth and Human S · Phase I · Next-generation aptamers for faster, safer, more sensitive in vivo PET imaging$300K
- Federal grantHealth and Human S · Phase I · Targeting SDF-1 for effective wet AMD treatment$250K
- Federal grantHealth and Human S · Phase II · Scalable High Quality Aptamer Generation via Chemically-Augmented Particle Display$224K
- Federal grantHealth and Human S · Phase II · Real-time Point of Care Insulin Monitoring Device for Improved Diabetes Management$793K
- Federal grantHealth and Human S · Phase I · Fully modified bispecific aptamer for effective wet AMD combination treatment$203K
- Federal grantHealth and Human S · Phase I · Fully modified bispecific aptamer for effective wet AMD combination treatment$203K
- Federal contractDefense · Igf::ot::igf Dhp 15.1A SBIR Ph II # H2-0189$1.0M
- Federal grantHealth and Human S · Phase I · Aptamer-Enabled High-sensitivity Troponin assay for rapid POC diagnosis of myocardial infarction$223K
- Federal grantHealth and Human S · Phase II · Particle display: a new paradigm in high throughput discovery of ultra-high perfo$625K
- Federal contractDefense · Igf::ot::igf SBIR Phase I Dhp 15.1 H151-012-0092$150K
- Federal grantHealth and Human S · Phase I · Real-time Point of Care Insulin Monitoring Device for Improved Diabetes Managemen$25K
- Federal grantHealth and Human S · Phase I · Real-time Continuous Intravenous Drug Monitor for Closed-Loop Anesthesia Delivery$220K
- Federal grantHealth and Human S · Phase I · Real-time Continuous Intravenous Drug Monitor for Closed-Loop Anesthesia Delivery$220K
- Federal grantHealth and Human S · Phase II · Particle display: a new paradigm in high throughput discovery of ultra-high perfo$1.5M
- Federal grantHealth and Human S · Phase II · Particle display: a new paradigm in high throughput discovery of ultra-high perfo$873K
Federal awards are summed by year (44 awards); hover a bar for the split. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#71 · top 14%
- Granted patents#85 · top 17%
- Linked publications#24 · top 5%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 4 granted of 19- GrantedAptamers and use thereofUSPTOUS 12,655,434
- PendingComposition And Method For Nucleic Acid DetectionUSPTOApplication 18546358
- PendingSystems And Methods For Sample AnalysisUSPTOApplication 18512233
Show all 19 patent records
- Aptamers and use thereofJun 16, 2026 · US 12,655,434Granted
- Composition And Method For Nucleic Acid DetectionMay 23, 2024 · Application 18546358Pending
- Systems And Methods For Sample AnalysisMay 16, 2024 · Application 18512233Pending
- Systems And Methods For Sample AnalysisJan 2, 2024 · US 11,857,962Granted
- Aptamers and use thereofMar 10, 2022 · Application 17463853Pending
- Compositions, Methods And Systems For Identifying Candidate Nucleic Acid AgentFeb 15, 2022 · US 11,248,231Granted
- Methods And Systems For Identifying Candidate Nucleic Acid AgentJun 22, 2021 · US 11,041,849Granted
- Use Of Nucleic Acid Agents For Ultra-sensitive Digital Detection And Quantification Of Target MoleculesOct 27, 2016 · Application 15107768Pending
- Methods And Systems For Identifying Candidate Nucleic Acid AgentApplication PCTUS2017061439Pending
- Compositions, Methods And Systems For Identifying Candidate Nucleic Acid AgentApplication PCTUS2017053578Pending
- Use Of Nucleic Acid Agents For Ultra-sensitive Digital Detection And Quantification Of Target MoleculesApplication PCTUS2015011464Pending
- Use Of Nucleic Acid Agents For Ultra-sensitive Digital Detection And Quantification Of Target MoleculesApplication 61927213Pending
- Composition And Method For Nucleic Acid DetectionApplication PCTUS2022016266Pending
- Aptamers And Use ThereofApplication PCTUS2021019649Pending
- Composition And Method For Nucleic Acid DetectionApplication 63149984Pending
- Systems And Methods For Sample AnalysisApplication 63149241Pending
- Aptamers and use thereofApplication 62984339Pending
- Aptamers And Use ThereofApplication PCTUS2020020743Pending
- Aptamers and use thereofApplication 62813192Pending
Recent research by its founders
- Functional genetic mutations in <i>LTF</i> influence its concentration in milk20261 cites
- Effects of Genetic and Environmental Factors on Reproductive Traits, with a Focus on Gestation Length in Sheep: Implications for Molecular Breeding—A Review20260 cites
- FAM216A and CCDC166 are not essential for male fertility20260 cites
Related companies, and why
- Soligenix, IncSimilar federal contract value in Biotech · $39.1M in contracts
- PROFECTUS BIOSCIENCES, INC.Similar federal contract value in Biotech · $38.3M in contracts
- Argos TherapeuticsSimilar federal contract value in Biotech · $38.2M in contracts
- AMGEN INCSimilar federal contract value in Biotech · $34.9M in contracts
- PLUS THERAPEUTICS, INC.Similar federal contract value in Biotech · $33.8M in contracts
- INTEGRAL MOLECULAR INCSimilar federal contract value in Biotech · $33.8M in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .